-
1
-
-
0037192458
-
Matrix metalloproteinase inhibitors and cancer: trials and tribulations
-
Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
-
(2002)
Science
, vol.295
, pp. 2387-2392
-
-
Coussens, L.M.1
Fingleton, B.2
Matrisian, L.M.3
-
2
-
-
0038364286
-
Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials
-
Pavlaki M., Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003, 22:177-203.
-
(2003)
Cancer Metastasis Rev
, vol.22
, pp. 177-203
-
-
Pavlaki, M.1
Zucker, S.2
-
3
-
-
79955447422
-
New opportunities in drug design of metalloproteinase inhibitors: combination between structure-function experimental approaches and systems biology
-
Sela-Passwell N., Trahtenherts A., Kruger A., Sagi I. New opportunities in drug design of metalloproteinase inhibitors: combination between structure-function experimental approaches and systems biology. Expert Opin Drug Discov 2011, 6:527-542.
-
(2011)
Expert Opin Drug Discov
, vol.6
, pp. 527-542
-
-
Sela-Passwell, N.1
Trahtenherts, A.2
Kruger, A.3
Sagi, I.4
-
4
-
-
36849073658
-
MMPs as therapeutic targets-still a viable option?
-
Fingleton B. MMPs as therapeutic targets-still a viable option?. Semin Cell Dev Biol 2008, 19:61-68.
-
(2008)
Semin Cell Dev Biol
, vol.19
, pp. 61-68
-
-
Fingleton, B.1
-
5
-
-
84876019734
-
Missing the target: matrix metalloproteinase antitargets in inflammation and cancer
-
Dufour A., Overall C.M. Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol Sci 2013, 34:233-242.
-
(2013)
Trends Pharmacol Sci
, vol.34
, pp. 233-242
-
-
Dufour, A.1
Overall, C.M.2
-
6
-
-
67949123229
-
Macrophage elastase kills bacteria within murine macrophages
-
Houghton A.M., Hartzell W.O., Robbins C.S., Gomis-Ruth F.X., Shapiro S.D. Macrophage elastase kills bacteria within murine macrophages. Nature 2009, 460:637-641.
-
(2009)
Nature
, vol.460
, pp. 637-641
-
-
Houghton, A.M.1
Hartzell, W.O.2
Robbins, C.S.3
Gomis-Ruth, F.X.4
Shapiro, S.D.5
-
7
-
-
84902964671
-
A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity
-
Marchant D.J., Bellac C.L., Moraes T.J., Wadsworth S.J., Dufour A., Butler G.S., et al. A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity. Nat Med 2014, 20:493-502.
-
(2014)
Nat Med
, vol.20
, pp. 493-502
-
-
Marchant, D.J.1
Bellac, C.L.2
Moraes, T.J.3
Wadsworth, S.J.4
Dufour, A.5
Butler, G.S.6
-
8
-
-
84863116229
-
MT1-MMP regulates the PI3Kdelta.Mi-2/NuRD-dependent control of macrophage immune function
-
Shimizu-Hirota R., Xiong W., Baxter B.T., Kunkel S.L., Maillard I., Chen X.W., et al. MT1-MMP regulates the PI3Kdelta.Mi-2/NuRD-dependent control of macrophage immune function. Genes Dev 2012, 26:395-413.
-
(2012)
Genes Dev
, vol.26
, pp. 395-413
-
-
Shimizu-Hirota, R.1
Xiong, W.2
Baxter, B.T.3
Kunkel, S.L.4
Maillard, I.5
Chen, X.W.6
-
9
-
-
74049088595
-
MT1-MMP is required for myeloid cell fusion via regulation of Rac1 signaling
-
Gonzalo P., Guadamillas M.C., Hernandez-Riquer M.V., Pollan A., Grande-Garcia A., Bartolome R.A., et al. MT1-MMP is required for myeloid cell fusion via regulation of Rac1 signaling. Dev Cell 2010, 18:77-89.
-
(2010)
Dev Cell
, vol.18
, pp. 77-89
-
-
Gonzalo, P.1
Guadamillas, M.C.2
Hernandez-Riquer, M.V.3
Pollan, A.4
Grande-Garcia, A.5
Bartolome, R.A.6
-
10
-
-
2142784516
-
MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover
-
Holmbeck K., Bianco P., Caterina J., Yamada S., Kromer M., Kuznetsov S.A., et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999, 99:81-92.
-
(1999)
Cell
, vol.99
, pp. 81-92
-
-
Holmbeck, K.1
Bianco, P.2
Caterina, J.3
Yamada, S.4
Kromer, M.5
Kuznetsov, S.A.6
-
11
-
-
0034635966
-
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I
-
Zhou Z., Apte S.S., Soininen R., Cao R., Baaklini G.Y., Rauser R.W., et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A 2000, 97:4052-4057.
-
(2000)
Proc Natl Acad Sci U S A
, vol.97
, pp. 4052-4057
-
-
Zhou, Z.1
Apte, S.S.2
Soininen, R.3
Cao, R.4
Baaklini, G.Y.5
Rauser, R.W.6
-
12
-
-
77954355093
-
Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration
-
Sabbota A.L., Kim H.R., Zhe X., Fridman R., Bonfil R.D., Cher M.L. Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res 2010, 70:5558-5566.
-
(2010)
Cancer Res
, vol.70
, pp. 5558-5566
-
-
Sabbota, A.L.1
Kim, H.R.2
Zhe, X.3
Fridman, R.4
Bonfil, R.D.5
Cher, M.L.6
-
13
-
-
0028302990
-
Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression
-
Sympson C.J., Talhouk R.S., Alexander C.M., Chin J.R., Clift S.M., Bissell M.J., et al. Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J Cell Biol 1994, 125:681-693.
-
(1994)
J Cell Biol
, vol.125
, pp. 681-693
-
-
Sympson, C.J.1
Talhouk, R.S.2
Alexander, C.M.3
Chin, J.R.4
Clift, S.M.5
Bissell, M.J.6
-
14
-
-
22344452580
-
Expression pattern of four membrane-type matrix metalloproteinases in the normal and diseased mouse mammary gland
-
Szabova L., Yamada S.S., Birkedal-Hansen H., Holmbeck K. Expression pattern of four membrane-type matrix metalloproteinases in the normal and diseased mouse mammary gland. J Cell Physiol 2005, 205:123-132.
-
(2005)
J Cell Physiol
, vol.205
, pp. 123-132
-
-
Szabova, L.1
Yamada, S.S.2
Birkedal-Hansen, H.3
Holmbeck, K.4
-
15
-
-
0141768243
-
Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis
-
Wiseman B.S., Sternlicht M.D., Lund L.R., Alexander C.M., Mott J., Bissell M.J., et al. Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis. J Cell Biol 2003, 162:1123-1133.
-
(2003)
J Cell Biol
, vol.162
, pp. 1123-1133
-
-
Wiseman, B.S.1
Sternlicht, M.D.2
Lund, L.R.3
Alexander, C.M.4
Mott, J.5
Bissell, M.J.6
-
16
-
-
84871568040
-
Transmembrane/cytoplasmic, rather than catalytic, domains of Mmp14 signal to MAPK activation and mammary branching morphogenesis via binding to integrin beta1
-
Mori H., Lo A.T., Inman J.L., Alcaraz J., Ghajar C.M., Mott J.D., et al. Transmembrane/cytoplasmic, rather than catalytic, domains of Mmp14 signal to MAPK activation and mammary branching morphogenesis via binding to integrin beta1. Development 2013, 140:343-352.
-
(2013)
Development
, vol.140
, pp. 343-352
-
-
Mori, H.1
Lo, A.T.2
Inman, J.L.3
Alcaraz, J.4
Ghajar, C.M.5
Mott, J.D.6
-
17
-
-
84876245148
-
The hemopexin domain of MMP3 is responsible for mammary epithelial invasion and morphogenesis through extracellular interaction with HSP90beta
-
Correia A.L., Mori H., Chen E.I., Schmitt F.C., Bissell M.J. The hemopexin domain of MMP3 is responsible for mammary epithelial invasion and morphogenesis through extracellular interaction with HSP90beta. Genes Dev 2013, 27:805-817.
-
(2013)
Genes Dev
, vol.27
, pp. 805-817
-
-
Correia, A.L.1
Mori, H.2
Chen, E.I.3
Schmitt, F.C.4
Bissell, M.J.5
-
18
-
-
84903286861
-
Diverse matrix metalloproteinase functions regulate cancer amoeboid migration
-
Orgaz J.L., Pandya P., Dalmeida R., Karagiannis P., Sanchez-Laorden B., Viros A., et al. Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. Nat Commun 2014, 5:4255.
-
(2014)
Nat Commun
, vol.5
, pp. 4255
-
-
Orgaz, J.L.1
Pandya, P.2
Dalmeida, R.3
Karagiannis, P.4
Sanchez-Laorden, B.5
Viros, A.6
-
19
-
-
76249124026
-
Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain
-
Redondo-Munoz J., Ugarte-Berzal E., Terol M.J., den Steen PE Van, Hernandez del Cerro M., Roderfeld M., et al. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell 2010, 17:160-172.
-
(2010)
Cancer Cell
, vol.17
, pp. 160-172
-
-
Redondo-Munoz, J.1
Ugarte-Berzal, E.2
Terol, M.J.3
Van den Steen, P.E.4
Hernandez del Cerro, M.5
Roderfeld, M.6
-
20
-
-
84881481410
-
Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets
-
Hadler-Olsen E., Winberg J.O., Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol 2013, 34:2041-2051.
-
(2013)
Tumour Biol
, vol.34
, pp. 2041-2051
-
-
Hadler-Olsen, E.1
Winberg, J.O.2
Uhlin-Hansen, L.3
-
21
-
-
34648815810
-
Emerging roles of proteases in tumour suppression
-
Lopez-Otin C., Matrisian L.M. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007, 7:800-808.
-
(2007)
Nat Rev Cancer
, vol.7
, pp. 800-808
-
-
Lopez-Otin, C.1
Matrisian, L.M.2
-
22
-
-
60649108677
-
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis
-
Devy L., Huang L., Naa L., Yanamandra N., Pieters H., Frans N., et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 2009, 69:1517-1526.
-
(2009)
Cancer Res
, vol.69
, pp. 1517-1526
-
-
Devy, L.1
Huang, L.2
Naa, L.3
Yanamandra, N.4
Pieters, H.5
Frans, N.6
-
23
-
-
84855536559
-
Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential
-
Sela-Passwell N., Kikkeri R., Dym O., Rozenberg H., Margalit R., Arad-Yellin R., et al. Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nat Med 2012, 18:143-147.
-
(2012)
Nat Med
, vol.18
, pp. 143-147
-
-
Sela-Passwell, N.1
Kikkeri, R.2
Dym, O.3
Rozenberg, H.4
Margalit, R.5
Arad-Yellin, R.6
-
25
-
-
61749094550
-
Optical imaging of matrix metalloproteinase-7 activity in vivo using a proteolytic nanobeacon
-
Scherer R.L., VanSaun M.N., McIntyre J.O., Matrisian L.M. Optical imaging of matrix metalloproteinase-7 activity in vivo using a proteolytic nanobeacon. Mol Imaging 2008, 7:118-131.
-
(2008)
Mol Imaging
, vol.7
, pp. 118-131
-
-
Scherer, R.L.1
VanSaun, M.N.2
McIntyre, J.O.3
Matrisian, L.M.4
-
26
-
-
84906940038
-
In vivo imaging of membrane type-1 matrix metalloproteinase with a novel activatable near-infrared fluorescence probe
-
Shimizu Y., Temma T., Hara I., Makino A., Kondo N., Ozeki E., et al. In vivo imaging of membrane type-1 matrix metalloproteinase with a novel activatable near-infrared fluorescence probe. Cancer Sci 2014, 105:1056-1062.
-
(2014)
Cancer Sci
, vol.105
, pp. 1056-1062
-
-
Shimizu, Y.1
Temma, T.2
Hara, I.3
Makino, A.4
Kondo, N.5
Ozeki, E.6
-
27
-
-
84863378692
-
Detection of MMP-2 and MMP-9 activity in vivo with a triple-helical peptide optical probe
-
Akers W.J., Xu B., Lee H., Sudlow G.P., Fields G.B., Achilefu S., et al. Detection of MMP-2 and MMP-9 activity in vivo with a triple-helical peptide optical probe. Bioconjug Chem 2012, 23:656-663.
-
(2012)
Bioconjug Chem
, vol.23
, pp. 656-663
-
-
Akers, W.J.1
Xu, B.2
Lee, H.3
Sudlow, G.P.4
Fields, G.B.5
Achilefu, S.6
-
28
-
-
84903703789
-
Fluorescence detection of MMP-9.II. Ratiometric FRET-based sensing with dually labeled specific peptide
-
Fudala R., Rich R., Mukerjee A., Ranjan A.P., Vishwanatha J.K., Kurdowska A.K., et al. Fluorescence detection of MMP-9.II. Ratiometric FRET-based sensing with dually labeled specific peptide. Curr Pharm Biotechnol 2014, 14:1134-1138.
-
(2014)
Curr Pharm Biotechnol
, vol.14
, pp. 1134-1138
-
-
Fudala, R.1
Rich, R.2
Mukerjee, A.3
Ranjan, A.P.4
Vishwanatha, J.K.5
Kurdowska, A.K.6
-
29
-
-
55749111198
-
Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model
-
Lebel R., Jastrzebska B., Therriault H., Cournoyer M.M., McIntyre J.O., Escher E., et al. Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model. Magn Reson Med 2008, 60:1056-1065.
-
(2008)
Magn Reson Med
, vol.60
, pp. 1056-1065
-
-
Lebel, R.1
Jastrzebska, B.2
Therriault, H.3
Cournoyer, M.M.4
McIntyre, J.O.5
Escher, E.6
-
30
-
-
37649020428
-
Noninvasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch
-
Lepage M., Dow W.C., Melchior M., You Y., Fingleton B., Quarles C.C., et al. Noninvasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch. Mol Imaging 2007, 6:393-403.
-
(2007)
Mol Imaging
, vol.6
, pp. 393-403
-
-
Lepage, M.1
Dow, W.C.2
Melchior, M.3
You, Y.4
Fingleton, B.5
Quarles, C.C.6
-
31
-
-
84896690165
-
Molecular imaging for cancer diagnosis and surgery
-
Hussain T., Nguyen Q.T. Molecular imaging for cancer diagnosis and surgery. Adv Drug Deliv Rev 2014, 66:90-100.
-
(2014)
Adv Drug Deliv Rev
, vol.66
, pp. 90-100
-
-
Hussain, T.1
Nguyen, Q.T.2
-
32
-
-
84880379236
-
Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT
-
Matusiak N., van Waarde A., Bischoff R., Oltenfreiter R., van de Wiele C., Dierckx R.A., et al. Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT. Curr Pharm Des 2013, 19:4647-4672.
-
(2013)
Curr Pharm Des
, vol.19
, pp. 4647-4672
-
-
Matusiak, N.1
van Waarde, A.2
Bischoff, R.3
Oltenfreiter, R.4
van de Wiele, C.5
Dierckx, R.A.6
-
33
-
-
77957374320
-
Novel matrix metalloproteinase inhibitor [18F]marimastat-aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancer
-
auf dem Keller U., Bellac C.L., Li Y., Lou Y., Lange P.F., Ting R., et al. Novel matrix metalloproteinase inhibitor [18F]marimastat-aryltrifluoroborate as a probe for in vivo positron emission tomography imaging in cancer. Cancer Res 2010, 70:7562-7569.
-
(2010)
Cancer Res
, vol.70
, pp. 7562-7569
-
-
auf dem Keller, U.1
Bellac, C.L.2
Li, Y.3
Lou, Y.4
Lange, P.F.5
Ting, R.6
-
34
-
-
84855423104
-
In vivo positron emission tomography imaging of protease activity by generation of a hydrophobic product from a noninhibitory protease substrate
-
Chuang C.H., Chuang K.H., Wang H.E., Roffler S.R., Shiea J.T., Tzou S.C., et al. In vivo positron emission tomography imaging of protease activity by generation of a hydrophobic product from a noninhibitory protease substrate. Clin Cancer Res 2012, 18:238-247.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 238-247
-
-
Chuang, C.H.1
Chuang, K.H.2
Wang, H.E.3
Roffler, S.R.4
Shiea, J.T.5
Tzou, S.C.6
-
35
-
-
71949091979
-
Polymeric nanoparticle-based activatable near-infrared nanosensor for protease determination in vivo
-
Lee S., Ryu J.H., Park K., Lee A., Lee S.Y., Youn I.C., et al. Polymeric nanoparticle-based activatable near-infrared nanosensor for protease determination in vivo. Nano Lett 2009, 9:4412-4416.
-
(2009)
Nano Lett
, vol.9
, pp. 4412-4416
-
-
Lee, S.1
Ryu, J.H.2
Park, K.3
Lee, A.4
Lee, S.Y.5
Youn, I.C.6
-
36
-
-
20044396354
-
Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity
-
Albright C.F., Graciani N., Han W., Yue E., Stein R., Lai Z., et al. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. Mol Cancer Ther 2005, 4:751-760.
-
(2005)
Mol Cancer Ther
, vol.4
, pp. 751-760
-
-
Albright, C.F.1
Graciani, N.2
Han, W.3
Yue, E.4
Stein, R.5
Lai, Z.6
-
37
-
-
20444471117
-
Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9
-
Kline T., Torgov M.Y., Mendelsohn B.A., Cerveny C.G., Senter P.D. Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9. Mol Pharm 2004, 1:9-22.
-
(2004)
Mol Pharm
, vol.1
, pp. 9-22
-
-
Kline, T.1
Torgov, M.Y.2
Mendelsohn, B.A.3
Cerveny, C.G.4
Senter, P.D.5
-
38
-
-
26944443171
-
Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model
-
Van Valckenborgh E., Mincher D., Di Salvo A., Van Riet I., Young L., Van Camp B., et al. Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model. Leukemia 2005, 19:1628-1633.
-
(2005)
Leukemia
, vol.19
, pp. 1628-1633
-
-
Van Valckenborgh, E.1
Mincher, D.2
Di Salvo, A.3
Van Riet, I.4
Young, L.5
Van Camp, B.6
-
39
-
-
34547891537
-
Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes
-
Hatakeyama H., Akita H., Ishida E., Hashimoto K., Kobayashi H., Aoki T., et al. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int J Pharm 2007, 342:194-200.
-
(2007)
Int J Pharm
, vol.342
, pp. 194-200
-
-
Hatakeyama, H.1
Akita, H.2
Ishida, E.3
Hashimoto, K.4
Kobayashi, H.5
Aoki, T.6
-
40
-
-
84885716472
-
Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety
-
Zhu L., Wang T., Perche F., Taigind A., Torchilin V.P. Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. Proc Natl Acad Sci U S A 2013, 110:17047-17052.
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, pp. 17047-17052
-
-
Zhu, L.1
Wang, T.2
Perche, F.3
Taigind, A.4
Torchilin, V.P.5
-
41
-
-
84855428544
-
New approaches for dissecting protease functions to improve probe development and drug discovery
-
Deu E., Verdoes M., Bogyo M. New approaches for dissecting protease functions to improve probe development and drug discovery. Nat Struct Mol Biol 2012, 19:9-16.
-
(2012)
Nat Struct Mol Biol
, vol.19
, pp. 9-16
-
-
Deu, E.1
Verdoes, M.2
Bogyo, M.3
-
42
-
-
84879325210
-
Coupling protein engineering with probe design to inhibit and image matrix metalloproteinases with controlled specificity
-
Morell M., Nguyen Duc T., Willis A.L., Syed S., Lee J., Deu E., et al. Coupling protein engineering with probe design to inhibit and image matrix metalloproteinases with controlled specificity. J Am Chem Soc 2013, 135:9139-9148.
-
(2013)
J Am Chem Soc
, vol.135
, pp. 9139-9148
-
-
Morell, M.1
Nguyen Duc, T.2
Willis, A.L.3
Syed, S.4
Lee, J.5
Deu, E.6
-
43
-
-
79551509386
-
Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2
-
Dangi-Garimella S., Krantz S.B., Barron M.R., Shields M.A., Heiferman M.J., Grippo P.J., et al. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res 2011, 71:1019-1028.
-
(2011)
Cancer Res
, vol.71
, pp. 1019-1028
-
-
Dangi-Garimella, S.1
Krantz, S.B.2
Barron, M.R.3
Shields, M.A.4
Heiferman, M.J.5
Grippo, P.J.6
-
44
-
-
84893578869
-
Induction of autophagy biomarker BNIP3 requires a JAK2/STAT3 and MT1-MMP signaling interplay in Concanavalin-A-activated U87 glioblastoma cells
-
Pratt J., Annabi B. Induction of autophagy biomarker BNIP3 requires a JAK2/STAT3 and MT1-MMP signaling interplay in Concanavalin-A-activated U87 glioblastoma cells. Cell Signal 2014, 26:917-924.
-
(2014)
Cell Signal
, vol.26
, pp. 917-924
-
-
Pratt, J.1
Annabi, B.2
-
45
-
-
0035216956
-
Matrilysin expression selects for cells with reduced sensitivity to apoptosis
-
Fingleton B., Vargo-Gogola T., Crawford H.C., Matrisian L.M. Matrilysin expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 2001, 3:459-468.
-
(2001)
Neoplasia
, vol.3
, pp. 459-468
-
-
Fingleton, B.1
Vargo-Gogola, T.2
Crawford, H.C.3
Matrisian, L.M.4
-
46
-
-
0035863471
-
Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity
-
Mitsiades N., Yu W., Poulaki V., Tsokos M., Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001, 61:577-581.
-
(2001)
Cancer Res
, vol.61
, pp. 577-581
-
-
Mitsiades, N.1
Yu, W.2
Poulaki, V.3
Tsokos, M.4
Stamenkovic, I.5
-
47
-
-
84892691559
-
Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients
-
Huang Y., Yu H., Lei H., Xie C., Zhong Y. Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients. Med Oncol 2014, 31:824.
-
(2014)
Med Oncol
, vol.31
, pp. 824
-
-
Huang, Y.1
Yu, H.2
Lei, H.3
Xie, C.4
Zhong, Y.5
-
48
-
-
62749191287
-
The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin
-
Almendro V., Ametller E., Garcia-Recio S., Collazo O., Casas I., Auge J.M., et al. The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin. PLoS One 2009, 4:e4728.
-
(2009)
PLoS One
, vol.4
-
-
Almendro, V.1
Ametller, E.2
Garcia-Recio, S.3
Collazo, O.4
Casas, I.5
Auge, J.M.6
-
49
-
-
70350348352
-
Chronic exposure to exogenous matrilysin induces chemoresistance and enhances Bcl-2 expression in A549 lung adenocarcinoma cells
-
Liu H., Zhang T., Wu B., Huang J., Zhou Y., Zhu J. Chronic exposure to exogenous matrilysin induces chemoresistance and enhances Bcl-2 expression in A549 lung adenocarcinoma cells. Mol Biol Rep 2009, 36:2099-2109.
-
(2009)
Mol Biol Rep
, vol.36
, pp. 2099-2109
-
-
Liu, H.1
Zhang, T.2
Wu, B.3
Huang, J.4
Zhou, Y.5
Zhu, J.6
-
50
-
-
34247521438
-
Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche
-
Psaila B., Kaplan R.N., Port E.R., Lyden D. Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche. Breast Dis 2006, 26:65-74.
-
(2006)
Breast Dis
, vol.26
, pp. 65-74
-
-
Psaila, B.1
Kaplan, R.N.2
Port, E.R.3
Lyden, D.4
-
51
-
-
28644432204
-
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
-
Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
-
(2005)
Nature
, vol.438
, pp. 820-827
-
-
Kaplan, R.N.1
Riba, R.D.2
Zacharoulis, S.3
Bramley, A.H.4
Vincent, L.5
Costa, C.6
-
52
-
-
57849100048
-
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche
-
Erler J.T., Bennewith K.L., Cox T.R., Lang G., Bird D., Koong A., et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009, 15:35-44.
-
(2009)
Cancer Cell
, vol.15
, pp. 35-44
-
-
Erler, J.T.1
Bennewith, K.L.2
Cox, T.R.3
Lang, G.4
Bird, D.5
Koong, A.6
-
53
-
-
70350231667
-
Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis
-
Huang Y., Song N., Ding Y., Yuan S., Li X., Cai H., et al. Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res 2009, 69:7529-7537.
-
(2009)
Cancer Res
, vol.69
, pp. 7529-7537
-
-
Huang, Y.1
Song, N.2
Ding, Y.3
Yuan, S.4
Li, X.5
Cai, H.6
-
54
-
-
84862007577
-
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
-
Peinado H., Aleckovic M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012, 18:883-891.
-
(2012)
Nat Med
, vol.18
, pp. 883-891
-
-
Peinado, H.1
Aleckovic, M.2
Lavotshkin, S.3
Matei, I.4
Costa-Silva, B.5
Moreno-Bueno, G.6
-
55
-
-
77953481684
-
Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation
-
McCready J., Sims J.D., Chan D., Jay D.G. Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation. BMC Cancer 2010, 10:294.
-
(2010)
BMC Cancer
, vol.10
, pp. 294
-
-
McCready, J.1
Sims, J.D.2
Chan, D.3
Jay, D.G.4
-
56
-
-
57149087260
-
Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes
-
Hakulinen J., Sankkila L., Sugiyama N., Lehti K., Keski-Oja J. Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. J Cell Biochem 2008, 105:1211-1218.
-
(2008)
J Cell Biochem
, vol.105
, pp. 1211-1218
-
-
Hakulinen, J.1
Sankkila, L.2
Sugiyama, N.3
Lehti, K.4
Keski-Oja, J.5
-
57
-
-
0032801787
-
Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro
-
Dolo V., D'Ascenzo S., Violini S., Pompucci L., Festuccia C., Ginestra A., et al. Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis 1999, 17:131-140.
-
(1999)
Clin Exp Metastasis
, vol.17
, pp. 131-140
-
-
Dolo, V.1
D'Ascenzo, S.2
Violini, S.3
Pompucci, L.4
Festuccia, C.5
Ginestra, A.6
|